Spectrum Pharmaceuticals Announces Second Quarter 2019 Financial Results Conference Call
August 01 2019 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it
will host a conference call with management to discuss the second
quarter 2019 financial results, provide an update on the company's
business, and discuss expectations for the future on Thursday,
August 8, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Conference Call:
Thursday, August
8, 2019 @ 4:30 p.m. Eastern/1:30 p.m. Pacific
Domestic: (877) 837-3910, Conference ID#
5378656
International: (973) 796-5077, Conference
ID# 5378656
For interested individuals unable to join the call, a replay
will be available from August 8, 2019 @ 7:30 p.m. ET/4:30 p.m. PT
through August 15, 2019 until 11:59 p.m. ET/8:59 p.m. PT.
Domestic Replay Dial-In #: (855) 859-2056,
Conference ID# 5378656
International Replay Dial-In #: (404)
537-3406, Conference ID# 5378656
This conference call will also be webcast. Listeners may access
the webcast, which will be available on the investor relations page
of Spectrum Pharmaceuticals' website:
http://investor.sppirx.com/events-and-presentations on August 8,
2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel and targeted
drug products, with a primary focus in hematology and oncology.
Spectrum has a strong track record of successfully executing across
the biopharmaceutical business model, from in-licensing and
acquiring differentiated drugs, clinically developing novel assets,
successfully gaining regulatory approvals and commercializing in a
competitive healthcare marketplace. Spectrum has a late-stage
pipeline with novel assets that serve areas of unmet need. This
pipeline has the potential to transform the company in the near
future. More information on Spectrum is available at
www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the company's reports filed with the Securities and
Exchange Commission. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER
CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2019 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190801005065/en/
Shiv Kapoor Vice President, Strategic Planning & Investor
Relations 702-835-6300 InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024